Single-cell transcriptome analysis of muscle and blood tissues from a patient with a rare homozygous ANO5 variant causing limb-girdle muscular dystrophy type R12
- 1Department of Rheumatology and Immunology, Tianjin Medical University General Hospital , ,
- 2Department of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University , ,
- 3Department of Neurology, Tianjin Medical University General Hospital , ,
Abstract
Background: Limb-girdle muscular dystrophy type R12 (LGMD R12) is a recessive genetic myopathy, typically caused by pathogenic variants in anoctamin-5 (ANO5), which encodes a multipass membrane protein localized to the sarcolemma and sarcoplasmic reticulum of muscle fibers. Effective therapeutic strategies for LGMD R12 remain elusive. A comprehensive analytical framework is required to dissect the cellular and molecular changes underlying this disease.
Methods: The ANO5 variant in the patient and his family members was validated by Sanger sequencing. We performed single-cell RNA sequencing analysis on biceps brachii muscle tissue (MUS) and peripheral blood mononuclear cells (PBMCs) from healthy controls (HCs) and a patient who was homozygous for the pathogenic variant in exon 10 of ANO5 (c.898dupA, p.Ile300fs). Immunofluorescence staining was conducted to validate key findings from the single-cell transcriptome analysis.
Results: In the MUS cell atlas , we observed a significant loss of type I muscle fibers in the patient with LGMD R12. Accordingly, immunofluorescence staining revealed a dramatic loss of MYH7+ cells (MYH7+, a marker of type I muscle fibers) compared with those in controls. Glycolytic pathway activity and cellular metabolic activity were significantly downregulated, suggesting that they are two transcriptomic signatures in the muscle tissue of this patient. In addition, muscle progenitor cells from the patient exhibited impaired differentiation capacity, failing to generate mature myocytes. In both MUS and PBMCs, we also observed heightened immune crosstalk accompanied by significant activation of pathways such as LGALS9–CD45/CD44 and ANXA1–FPR1, suggesting immunological activation in this patient.
Conclusion: LGMD R12 with pathogenic ANO5 variants is a rare genetic disease. Our transcriptome and experimental analyses revealed dramatic cellular and molecular changes in affected tissue at the single-cell resolution in a patient with LGMD R12. This study provides valuable insights into the underlying mechanisms and potential development of interventions for this recessive genetic myopathy.
Related
- Phenotype rescue through the restoration of full-length dystrophin using CRISPR/Cas9 genome editing in Duchenne muscular dystrophy patient-derived iPSCs carrying the deletion of two exons
- If Becker Muscular Dystrophy Initially Manifests with Heart Disease and Rhabdomyolysis, Neurological Work-up Is Imperative
- Planar covariation: a new key for the early detection of Duchenne muscular dystrophy walking behaviour
- Non-invasive adjunctive diagnostic models incorporating high-frequency ultrasound and shear wave elastography for pediatric Duchenne muscular dystrophy
- Image-based assessment of muscle contractile performance in facioscapulohumeral muscular dystrophy: protocol of the MUSCLE+ observational study in the Netherlands
BibTeX
@article{chen2026singlecell,
title = {{Single-cell transcriptome analysis of muscle and blood tissues from a patient with a rare homozygous ANO5 variant causing limb-girdle muscular dystrophy type R12}},
author = {Ming Chen and Ge Dong and Yue Wang and Jingjing Liu and Zhiqin Wang and Dengyi Bao and Zhiqiang Huang and Xiaowen Li and Yanmei Li and Zhigang Cai and Wei Wei},
journal = {Frontiers in genetics},
year = {2026},
month = oct,
doi = {10.3389/fgene.2026.1833196},
url = {https://europepmc.org/article/PMC/PMC13724551},
note = {CC BY},
}
RIS
TY - JOUR
TI - Single-cell transcriptome analysis of muscle and blood tissues from a patient with a rare homozygous ANO5 variant causing limb-girdle muscular dystrophy type R12
AU - Ming Chen
AU - Ge Dong
AU - Yue Wang
AU - Jingjing Liu
AU - Zhiqin Wang
AU - Dengyi Bao
AU - Zhiqiang Huang
AU - Xiaowen Li
AU - Yanmei Li
AU - Zhigang Cai
AU - Wei Wei
PY - 2026
DA - 2026/10/19
JO - Frontiers in genetics
DO - 10.3389/fgene.2026.1833196
UR - https://europepmc.org/article/PMC/PMC13724551
AB - Background: Limb-girdle muscular dystrophy type R12 (LGMD R12) is a recessive genetic myopathy, typically caused by pathogenic variants in anoctamin-5 (ANO5), which encodes a multipass membrane protein localized to the sarcolemma and sarcoplasmic reticulum of muscle fibers. Effective therapeutic strategies for LGMD R12 remain elusive. A comprehensive analytical framework is required to dissect the cellular and molecular changes underlying this disease. Methods: The ANO5 variant in the patient and his family members was validated by Sanger sequencing. We performed single-cell RNA sequencing analysis on biceps brachii muscle tissue (MUS) and peripheral blood mononuclear cells (PBMCs) from healthy controls (HCs) and a patient who was homozygous for the pathogenic variant in exon 10 of ANO5 (c.898dupA, p.Ile300fs). Immunofluorescence staining was conducted to validate key findings from the single-cell transcriptome analysis. Results: In the MUS cell atlas , we observed a significant loss of type I muscle fibers in the patient with LGMD R12. Accordingly, immunofluorescence staining revealed a dramatic loss of MYH7+ cells (MYH7+, a marker of type I muscle fibers) compared with those in controls. Glycolytic pathway activity and cellular metabolic activity were significantly downregulated, suggesting that they are two transcriptomic signatures in the muscle tissue of this patient. In addition, muscle progenitor cells from the patient exhibited impaired differentiation capacity, failing to generate mature myocytes. In both MUS and PBMCs, we also observed heightened immune crosstalk accompanied by significant activation of pathways such as LGALS9–CD45/CD44 and ANXA1–FPR1, suggesting immunological activation in this patient. Conclusion: LGMD R12 with pathogenic ANO5 variants is a rare genetic disease. Our transcriptome and experimental analyses revealed dramatic cellular and molecular changes in affected tissue at the single-cell resolution in a patient with LGMD R12. This study provides valuable insights into the underlying mechanisms and potential development of interventions for this recessive genetic myopathy.
SN - 1664-8021
ER -